Sudden cardiac death

Current Problems in Cardiology

Volumn 24, Issue 8, 1999, Pages 461-538

  Sra, Jasbir ^a   Dhala, Anwer ^a   Blanck, Zalmen ^a   Deshpande, Sanjay ^a   Cooley, Ryan ^a   Akhtar, Masood ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRHYTHMOGENESIS; ARTICLE; CORONARY ARTERY DISEASE; HEART DEATH; HEART HYPERTROPHY; HIGH RISK POPULATION; LONG QT SYNDROME; PRIMARY PREVENTION; RESUSCITATION; SECONDARY PREVENTION; SUDDEN DEATH; VALVULAR HEART DISEASE; ADULT; CARDIOMYOPATHY; CHILD; DEFIBRILLATOR; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; MALE; REVIEW; RISK FACTOR;

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIOMYOPATHIES; CHILD; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HEART VALVE DISEASES; HUMANS; LONG QT SYNDROME; MALE; RISK FACTORS;

EID: 0033176021     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0146-2806(99)90004-x     Document Type: Article

References (220)

1. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, editor. Heart disease: A textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders; 1992. p. 756-89.
2. Englestein ED, Zipes DP. Sudden cardiac death. In: Alexander RW, Schlant RC, Fuster V, editors. The heart, arteries, and veins. New York: McGraw-Hill; 1998. p. 1081-112.
3. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation 1989;79:756-65.
4. Manolio TA, Furberg CD. Epidemiology of sudden cardiac death. In: Akhtar M, Myerburg RJ, Ruskin, JN, editors. Sudden cardiac death: prevalence, mechanisms, and approaches to diagnosis and management. Philadelphia: Williams & Wilkins; 1994. p. 3-20.
5. Kuller LH, Perper JA, Dai WS, et al. Sudden death and the decline in coronary heart disease mortality. J Chronic Dis 1986;39:1001-19.
6. National Center for Health Statistics. Vital statistics of the United States. 1984. Vol II. Mortality Part A. Department of Health and Human Services publication No. (PHS) 87-1122. Washington (DC): Public Health Service, U.S. Government Printing Office; 1987.
7. Kuller L, Lilienfeld A, Fisher R. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation 1966;34:1056-68.
8. Kannel WB, Cupples LA, D'Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J 1987;113:799-804.
9. Perper JA, Kuller LH, Cooper M. Arteriosclerosis of coronary arteries in sudden unexpected deaths. Circulation 1975;52(6 Suppl):III27-33.
10. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-9.
11. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: structure, function and time-dependence of risk. Circulation 1992;85(suppl 1):I-2-I-10.
12. Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983;309:197-204.
13. Sra JS, Anderson AJ, Sheikh SH, et al. Unexplained syncope evaluated by electrophysiologic studies and head-tilt testing. Ann Intern Med 1991;114:1013-9.
14. Demirovic J. Risk factors in the incidence of sudden cardiac death and possibilities for its prevention [doctoral thesis]. Belgrade: University of Belgrade; 1985.
15. Gillum RF, Liu KC. Coronary heart disease mortality in United States blacks. 1940-1978: Trends and unanswered questions. Am Heart J 1984;108:728-32.
16. Gillum RF. Coronary heart disease in black populations: I. mortality and morbidity. Am Heart J 1982;104:839-51.
17. Report of the Secretary's Task Force on Black and Minority Health. Volume IV: cardiovascular and cerebrovascular disease. Part I. Washington (DC): U.S. Department of Health and Human Services; 1986. p. 97.
18. Weaver WD, Lorch GS, Alvarez HA, et al. Angiographic findings and prognostic indicators in patients resuscitated from sudden cardiac death. Circulation 1976; 54:895-900.
19. Farb A, Tang A, Burke A, et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischemic death. Eur Heart J 1989;10:203-8.
20. Chiang B, Perlman HV, Fulton M, et al. Predisposing factors in sudden cardiac death in Tecumseh, Michigan: a prospective study. Circulation 1970;41:31-7.
21. Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137-40.
22. Wang JS, Jen CJ, Kung HC, Lin LJ, Hsiue TR, Chen HI. Different effects of strenous exercise and moderate exercise on platelet function in men. Circulation 1994;90:2877-85.
23. Myerburg RJ, Kessler KM, Bassett Al, et al. A biological approach to sudden cardiac death: structure, function, and cause. Am J Cardiol 1989;63:1512-6.
24. Myerburg RJ, Kessler KM, Zaman L, et al. Pharmacologic approaches to the management of arrhythmias in patients with cardiomyopathy and heart failure. Am Heart J 1987;114:1273-9.
25. Myerburg JR, Kimura S, Kozlovskis PL, et al. Arrhythmias and the healed myocardial infarction. In: Rosen MR, Palti Y, editors. Lethal aarrhythmias resulting from myocardial ischemia and infarction. Boston: Kluwer Academic Publishers; 1988. p. 22-41.
26. Kleiger RE, Miller JP, Bigger JT Jr, et al. for the Multicenter Postinfarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction: a prospective study. Circulation 1988;78:816-24.
27. LaRovere MT, Specchia G, Mortara A, et al. Baroflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: a prospective study. Circulation 1988;78:816-24.
28. Rosen MR, Janse MJ, Myerburg MJ. Arrhythmias induced by coronary artery occlusion: what are the electrophysiologic mechanisms? In: Hears D, Manning A, Janse M, editors. Life-threatening arrhythmias during ischemia and infarction. New York: Raven Press; 1987. pp 11-47.
29. Wellens HJ, Duren LR, Lie KI. Observations on mechanisms of ventricular tachycardia in man. Circulation 1976;54;237-44.
30. Josephson ME, Horowitz LN, Farshidi A, et al. Recurrent sustained ventricular tachycardia. I: mechanisms. Circulation 1978;57:431-40.
31. Akhtar M. Clinical spectrum of ventricular tachycardia. Circulation 1990;82;1561-73.
32. El-Sherif N, Mehra R, Gough WB, et al. Reentrant ventricular arrhythmias in the late myocardial infarction period: interruption of reentrant circuits by cryothermal techniques. Circulation 1983;68:644-56.
33. Cheitlin MD, DeCastro CN, McAllister HA. Sudden death as a complication of left coronary origin from the right sinus of Valsava: a not so minor anomaly. Circulation 1974;50:780-7.
34. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol 1985;5:118B-121B.
35. Akagi T, Rose V, Benson LN, et al. Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr 1992;121:689-94.
36. Campbell M. The natural history of congenital aortic stenosis. Br Heart J 1968;30:514-26.
37. Narasimhan C, Jazayeri MR, Sra J, et al. Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery. Circulation 1997;96:4307-13.
38. Blackstone EH, Kriklin JW. Death- and time-related events after valve replacement. Circulation 1985;74:753-67.
39. Doval HC, Nul DR, Grancelli HO, et al. and the GESICA-GEMA Investigators. Nonsustained ventricular tachycardia in severe heart failure: independent marker of increased mortality due to sudden death. Circulation 1997;94:3198-203.
40. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993;88:2953-61.
41. Marian AJ, Roberts R. Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998;9: 88-99.
42. Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 1992;124:1035-45.
43. Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993;4:253-62.
44. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
45. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation 1968;37:759-88.
46. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:844-52.
47. Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertophic cardiomyopathy in an outpatient population. N Engl J Med 1989;320:749-55.
48. Watkins H, McKenna WJ, Thierfedler L, et al. Mutations in the genes for cardiac tropinin T and α-tropomyosin in hypertropyic cardiomyopathy. N Engl J Med 1995;332:1058-64.
49. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-6.
50. DeRose JJ Jr, Banas JS Jr, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994;36:475-84.
51. Maron BJ, Lipson LC, Roberts WC, et al. "Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978;41:1133-40.
52. Geibel A, Brugada P, Zehender M, et al. Value of programmed electrical stimulation using a standardized ventricular stimulation protocol in hypertrophic cardiomyopathy. Am J Cardiol 1987;60:738-9.
53. Kuck K-H, Kunze KP, Schluter M. Programmed electrical stimulation in hypertrophic cardiomyopathy: results in patients with and without cardiac arrest or syncope. Eur Heart J 1988;9:177-85.
54. Fananapazir L, Chang Ac, Epstein SE. Prognostic determinants of hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiologic findings. Circulation 1992;86:730-40.
55. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388-94.
56. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. J Am Med Assoc 1996;276:199-204.
57. Zhu DWX, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. PACE 1998 21:299-302.
58. McKenna WJ, Deanfeld J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-8.
59. Fananapazir L, Leon MB, Bonow RO. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67:169-74.
60. Saumarez RC, Slade AK, Grace AA, et al. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy: a prospective study. Circulation 1995;91:2762-8.
61. Corrado D, Basso C. Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997;30:1512-20.
62. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988;318:129-33.
63. Marcus FL, Fontaine GH, Guidaudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1992;65:384-98.
64. Marcus FL, Fontaine GH, Frank R, et al. Long term follow-up in patients with arrhythmogenic right ventricular disease. Eur Heart J 1989;10(suppl D):68-73.
65. Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985;87:476-82.
66. Sika MJ, Kron J, Walance CG, et al. Assessment and follow-up of pediatric survivors of sudden cardiac death. Circulation 1982;82:341-9.
67. Dunnigan A. Pritzker MR, Benditt DG, et al. Life threatening ventricular tachycardia in late survivors of surgically corrected tetralogy of Fallot. Br Heart J 1984;52:198-206.
68. Garson Jr, A. Sudden death in a pediatric cardiology population, 1958-1983. In: Morganroth J, Horowitz LN, editors. Sudden cardiac death. New York: Grune & Stratton; 1985. p. 47-56.
69. Lambert EC, Menon VA, Wagner HR, et al. Sudden unexpected death from cardiovascular disease in children: a cooperative international study. Am J Cardiol 1974; 34:89-96.
70. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991;68:1388-92.
71. Harris P, Alexson C, Lewis E, et al. Sudden unexpected cardiac death in adolescence: In: Proceedings of the Second World Congress of Pediatric Cardiology. New York: Springer-Verlag; 1985. p. 1183-5.
72. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986;7:204-14.
73. Bharati S, Lev M. Congenital abnormalities of the conduction system in sudden death in young adults. J Am Coll Cardiol 1986;8:1096-104.
74. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991;84:1136-44.
75. Romano C, Gemme G. Pongiglione R. Arithmic cardiache rare in età peidatrica. Clin Pediatr 1963;45:656-83.
76. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc 1964; 54:103-6.
77. Fraser GR, Froggatt P, Murphy T. Genetical aspects of the cardio-auditory syndrome of Jervell and Lange-Nielsen (congenital deafness and electrocardiographic abnormalities). Ann Hum Genet 1964;28:133-56.
78. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995;92:2929-34.
79. Roden DM, Woolsley RL, Primm RK, et al. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986;111:1088-93.
80. Roden DM. The long QT syndrome and torsades de pointes. In: El-Sherif N, Samet P, editors. Basic and clinical aspects: cardiac pacing and electrophysiology. 1st ed. Philadelphia: WB Saunders; 1991.
81. Sra J, Akhtar M. Recent advances in understanding the mechanisms, diagnosis, and treatment of congenital and acquired long QT syndrome. Indian Heart J 1996; 48:639-51.
82. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
83. Viskin S, Lesh MD, Eldar M, et al. Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 1997;8:1115-20.
84. Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsades de pointes: a new electrocardiographic entity in the spectrum of idiopathic ventricular tachycardias. Circulation 1994;89:206-15.
85. Leenhardt A, Lucet V, Denjoy I, et al. Catchecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients. Circulation 1995;91:1512-9.
86. Brugada P, Brugada J. A distinct clinical and electrocardiographic syndrome: right bundle branch block, persistent ST segment elevation with normal QT interval and sudden cardiac death [abstract]. PACE 1991;14:746.
87. 3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-60.
88. Nademanee K, Veerakul G, Mimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997;96:2595-600.
89. Kasanuki H, Ohnishi S, Ohtuka M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997;95:2277-85.
90. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol 1993;4:356-68.
91. Wellens HJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Am J Cardiol 1974;34:777-82.
92. Bromberg BI, Lindsay BD, Cain ME, Xox JL. Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolf-Parkinson-White syndrome. J Am Coll Cardiol 1996;27:690-5.
93. Cobb LA, Baum RS, Alvarez H, et al. Survival after resuscitation from out-of-hospital ventricular fibrillation: 4-yeas follow-up. Circulation 1975;52(suppl III):III-223-III-235.
94. Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988; 318:19-24.
95. Swerdlow CD, Winkle RA, Mason JW, et al. Determinants of survival in patients with ventricular tachyarrhythmias. New Eng J Med 1983;308;1436-42.
96. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, LV dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250-8.
97. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a review. PACE 1995;18:1298-314.
98. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987;9:531-8.
99. Schoenfeld MH, McGovern BA, Garan H, et al. Determinants of the outcome of electrophysiologic study in patients with ventricular arrhythmias. J Am Coll Cardiol 1985;6:298-306.
100. Roy D, Waxman HL, Kienzle MG, et al. Clinical characteristics and long-term follow-up in 119 survivors of cardiac arrest: relation to inducibility at electrophysiologic testing. Am J Cardiol 1983;52:969-74.
101. Kelly P, Ruskin JN, Vlahakes GJ, et al. Surgical coronary revascularization in survivors of pre-hospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990;15:267-73.
102. Wang YS, Scheinman MM, Chien WW, et al. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up. J Am Coll Cardiol 1991;18:1711-9.
103. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with LV dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
104. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
105. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of randomized trials. Prog Cardiovasc Dis 1985;27(5):335-71.
106. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981;ii:823-7.
107. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;ii:57-66.
108. Herlitz J, Elmfeldt D, Holmberg S, et al. Goteborg Metoprolol Trial: mortality and causes of death. Am J Cardiol 1984;53:9D-14D.
109. Herlitz J, Hjalmarson A, Swedberg K, et al. Effects on mortality during 5 years after early intervention with metoprolol in suspected acute myocardial infarction. Acta Med Scand 1988;223:227-31.
110. MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomised, placebo-controlled international trial. Eur Heart J 1985;6:199-226.
111. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study. BMJ 1975;3:435-40.
112. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304:801-7.
113. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with myocardial infarction: I. Mortality results. JAMA 1982; 247:1707-17.
114. Yusuf S, Sleight P, Rossi P, et al. Reduction of infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983;67(suppl):I-32-I-41.
115. Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP) Subgroup findings from randomised trials in post infarction patients. Eur Heart J 1988;9:8-16.
116. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
117. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994;74:674-80.
118. Kennedy HL, Rosenson RS. Physician use of beta-adrenergic blocking therapy: a changing perspective. J Am Coll Cardiol 1995;26:547-52.
119. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. J Am Med Assoc 1997;277:115-21.
120. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
121. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16.
122. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995; 92:3132-7.
123. The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
124. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 1986;314:1547-52.
125. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazineisosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:351-3.
126. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:6585-691.
127. The TRACE Study Group. The TRAndolapril Cardiac Evaluation (TRACE) Study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1994;73:44C-50C.
128. Swedberg K, Held P, Kjekshus J, et al. for the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
129. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
130. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
131. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
132. Kingma JH, van Gilst WH, Peels CH, et al. Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J 1994;15:898-907.
133. Ambrosioni E, Borghi C, Magnani B for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensinconverting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
134. Ball SG, Reynolds GW, Murray GD. ACE inhibitors after myocardial infarction. Lancet 1994;343:1132.
135. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995;333:1301-7.
136. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
137. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
138. ISIS Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2. Lancet 1988;2:349-60.
139. Fourth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Chest 1995;108(suppl):225S-522S.
140. Leader SG, Mallick R, Briggs NC. Myocardial infarction in newly diagnosed hypertensive Medicaid patients free of coronary heart disease and treated with calcium channel blockers. Am J Med 1997;102:150-7.
141. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. J Am Med Assoc 1995;274:620-5.
142. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
143. Braun S, Boyko V, Behar S, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol 1996;28:7-11.
144. Aursnes I, Litleskare I, Froyland H, et al. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Press 1995;4:157-63.
145. Jick H, Derby LE, Gurewich V, et al. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996;16:321-6.
146. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial-II (DAVIT II). Am J Cardiol 1990;66:779-85.
147. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319:385-92.
148. Packer M, O'Connor CM, Ghali JK, et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
149. Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens 1996;14:1237-45.
150. The DEFIANT-II Research Group. Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of DEFIANT-II Study. Eur Heart J 1997;18:31-40.
151. Holmes DR Jr, Davis KB, Mock MB, et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease. a report from the Coronary Artery Surgery Study. Circulation 1986;73:1254-63.
152. European Coronary Surgery Study Group. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982;ii:1173-80.
153. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
154. Stack RS, Califf RM, Hinohara T, et al. Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1988;11:1141-9.
155. Sager PT, Perlmutter RA, Rosenfeld LE, et al. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol 1988;12:19-24.
156. Impact Research Group: International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984; 4:1148-63.
157. U.K. Rhythmodan Multicenter Study Group: oral disopyramide after admission to hospital with suspected acute myocardial infarction. Postgrad Med J 1984;60:98-107.
158. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991:324:781-8.
159. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
160. Julian DG, Prescott RJ, Jackson FS, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;i:1142-7.
161. Waldo AL, Camm AJ, deRuyter H, et al. for the SWORD investigators. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
162. Nademanee K, Singh BN, Stevenson WG, et al. Amiodarone and post-MI patients. Circulation 1993;88:764-74.
163. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-8.
164. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991;84:550-7.
165. Ceremuzynski Z, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-62.
166. Navarro-Lopez F, Cosin J, Marrugat J, et al. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol 1993;72:1243-8.
167. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-8.
168. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333: 77-82.
169. Cairns JA, Connolly SJ, Roberts R, et al. for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.
170. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction. EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-74.
171. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983:309:331-6.
172. Wilber DJ, Olshansky B, Moran JF, et al. Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation 1990;82:350-8.
173. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
174. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993;87:312-22.
175. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Circulation 1998;97:2129-35.
176. Bigger JT Jr for the Coronary Artery Bypass Graft (CABG) Patch trial investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997;337:1569-75.
177. Buxton AE, Fisher JD, Josephson ME, et al. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993;36:215-26.
178. Herre JM, Sauve MJ, Malone P, et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989;13:442-9.
179. Fogoros RN, Elson JJ, Bonnet CA, et al. Long-term outcome of survivors of cardiac arrest whose therapy is guided by electrophysiologic testing. J Am Coll Cardiol 1992;19:780-8.
180. Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter defibrillator. J Am Coll Cardiol 1989;13:1353-61.
181. Akhtar M, Avitall B, Jazayeri M, et al. Role of implantable cardioverter defibrillator therapy in the management of high risk patients. Circulation 1992;85(suppl I):I-131-I-9.
182. Powell AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-92.
183. Mason JW, The ESVEM Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329:445-51.
184. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993;72:280-7.
185. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug-therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
186. Natale A, Sra J, Axtell K, Maglio C, et al. Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: Does bypass surgery suffice? J Cardiovasc Electrophysiol 1994;5:988-94.
187. Guiraudon G, Fontaine G, Frank R, et al. Encircling endocardial ventriculotomy: a new surgical treatment for life-threatening ventricular tachycardias resistant to medical treatment following myocardial infarction. Ann Thorac Surg 1978;26:438-44.
188. Josephson ME, Harken AH, Horowitz LN. Endocardial excision: a new surgical technique for the treatment of recurrent ventricular tachycardia. Circulation 1979; 60:1430-9.
189. Haines DE, Lerman BB, Kron IL, et al. Surgical ablation of ventricular tachycardia with sequential map-guided subendocardial resection: electrophysiologic assessment and long-term follow-up. Circulation 1988;77:131-41.
190. Cox JL. Patient selection criteria and results of surgery for refractory ischemic ventricular tachycardia. Circulation 1989;79(suppl I):I-163-I-77.
191. Wittig JM, Boineau JP. Surgical treatment of ventricular arrhythmias using epicardial, transmural, and endocardial mapping. Ann Thorac Surg 1975;20:117-21.
192. Swedberg K, Hjalmarson A, Waagstein F, et al. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-33.
193. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-5.
194. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
195. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
196. Tchou P, Jazayeri M, Denker S, et al. Transcatheter electrical ablation of right bundle branch: a method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988;78:246-57.
197. Caceres J, Jazayeri M, McKinnie J, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989;79:256-70.
198. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J 1985;109:399-411.
199. Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: a worldwide report. Circulation 1991;84:1414-9.
200. Eldar M, Griffin JC, Abbott JA, et al. Efficacy of permanent cardiac pacing in patients with the long QT syndrome. J Am Coll Cardiol 1987;10:600-7.
201. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high risk patients with long QT syndrome. Circulation 1991;84:1524-9.
202. Garson A Jr, Dick M II, Fournier A, et al. The long QT syndrome in children: an international study of 287 patients. Circulation 1993;87:1866-72.
203. + channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation 1995;92:3381-6.
204. Zareba W, Moss AJ, le Cessie S, et al. Risk of cardiac events in family members of patients with long QT syndrome. J Am Coll Cardiol 1995;26:1685-91.
205. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsades de pointes: the long-short initiating sequence and other clinical features. Observations in 32 patients. J Am Coll Cardiol 1983;2:806-17.
206. Kuck KH, Kunze KP, Bleifeld W. Sotalol-induced torsades de pointes. Am Heart J 1984;107:179-80.
207. Tzivoni D, Keren A, Cohen AM. Magnesium therapy for torsades de pointes. Am J Cardiol 1984;53:528-31.
208. Carlsson L, Abrahamsson C, Drews L, et al. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed after repolarization. Circulation 1992;85:16271-91.
209. Myerburg RJ, Conde CA, Sung RJ, et al. Clinical, electrophysiologic and hemodynamic profile of patients resuscitated from prehospital cardiac arrest. Am J Med 1980;68:568-76.
210. Hallstrom AP, Eisenburg MS, Bergner I. The persistence of ventricular fibrillation and its implications for evaluating EMS. Emerg Health Serv Q 1983;1:42-7.
211. Weaver WD, Hill D, Faherbruch CE, et al. Use of the automatic external defibrillator in the management of out-of-hospital cardiac arrest. N Engl J Med 1988;319:661-6.
212. Eisenberg MS, Bergner L, Hallstrom A. Cardiac resuscitation in the community: importance of rapid provision and implications for program planning. JAMA 1979;241:1905-7.
213. Cummins RO, Ornato P, Thies WH, et al. Improving survival from sudden cardiac arrest. The "chain of survival" concept. Circulation 1991;83:1832-47.
214. de Vreede Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al, Out-of-hospital cardiac arrest in the 1990s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997;30:1500-5.
215. Colquhoun MC. Use of defibrillators by general practictioners. Br Med J 1988; 297;336-7.
216. Eisenberg MS, Moore J, Cummins RO, et al. Use of the automatic external defibrillator in home of survivors of out-of-hospital ventricular fibrillation. Am J Cardiol 1989;63:443-6.
217. Swenson RD, Hill DL, Martin JS, et al. Automatic external defibrillators used by family members to treat cardiac arrest [abstract]. Circulation 1987;76(suppl IV):IV-463.
218. Weaver D, Sutherland K, Wirkus MJ, et al. Emergency medical care requirements for large public assemblies and a new strategy for managing cardiac arrest in this setting. Ann Emerg Med 1989;18:155-60.
219. Cummins RO. From concept to standard-of-care? Review of the clinical experience with automated external defibrillators. Ann Emerg Med 1989;18:1269-75.
220. Weisfeldt ML, Kerber RE, McGoldrick RP, et al. for the American Heart Assocation Task Force on Automatic External Defibrillation. Public access defibrillation. Circulation 1995;92:2763.